Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-3.25 Insider Own3.10% Shs Outstand43.27M Perf Week15.92%
Market Cap1.51B Forward P/E- EPS next Y-2.60 Insider Trans-6.81% Shs Float37.25M Perf Month39.82%
Income-123.50M PEG- EPS next Q-0.75 Inst Own82.00% Short Float16.73% Perf Quarter44.94%
Sales11.00M P/S136.89 EPS this Y-47.00% Inst Trans0.55% Short Ratio4.93 Perf Half Y113.24%
Book/sh4.30 P/B8.09 EPS next Y13.00% ROA-37.10% Target Price33.21 Perf Year87.70%
Cash/sh6.83 P/C5.09 EPS next 5Y- ROE-70.20% 52W Range13.12 - 36.00 Perf YTD13.24%
Dividend- P/FCF- EPS past 5Y- ROI-54.10% 52W High-3.33% Beta-
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low165.24% ATR2.29
Employees89 Current Ratio10.10 Sales Q/Q530.00% Oper. Margin- RSI (14)64.48 Volatility7.36% 7.66%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.80% Profit Margin- Rel Volume2.00 Prev Close34.62
ShortableYes LT Debt/Eq0.19 EarningsFeb 06 AMC Payout- Avg Volume1.26M Price34.80
Recom2.50 SMA2011.55% SMA5025.28% SMA20061.71% Volume2,521,771 Change0.52%
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Jan-23-18 03:50PM  2 Gene Editing Stocks SunTrust Recommends Benzinga
09:48AM  Forget Penny Stocks: Your Money Is Better Off in These 3 Companies Motley Fool
Jan-22-18 04:27PM  Here's Why Editas Medicine Gained as Much as 14.2% Today Motley Fool +13.88%
07:30AM  Market Trends Toward New Normal in Editas Medicine, Impinj, Neos Therapeutics, Nordson, National Western Life Group, and Square Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-16-18 07:34AM  CRISPR Gene-Editing Stocks Going Down the Tubes? Think Again Motley Fool -6.19%
Jan-08-18 01:49PM  Editas lower on questions about Crispr efficacy CNBC Videos -10.63%
09:00AM  Editas Medicine Reports on Recent Progress and Announces EM22 Five-year Goals at J.P. Morgan Healthcare Conference GlobeNewswire
08:52AM  What Should We Expect From Editas Medicine Incs (NASDAQ:EDIT) Earnings In The Years Ahead? Simply Wall St.
08:00AM  Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless Motley Fool
07:07AM  3 Soaring Gene-Editing Biotech Stocks: Which Is the Best Buy? Motley Fool
Jan-03-18 08:57AM  Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-18 04:51PM  Is This Why Editas Medicine Is Surging Today? Motley Fool +11.68%
Dec-27-17 07:30PM  3 Stocks That Feel Like Netflix in 2002 Motley Fool
02:35PM  Want To Invest In Editas Medicine Inc (NASDAQ:EDIT)? Heres How It Performed Lately Simply Wall St.
Dec-26-17 06:04AM  3 Stocks That Could Make You Rich Motley Fool
Dec-22-17 12:32PM  CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know Motley Fool +6.44%
03:00AM  Editas Medicine Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Dec-19-17 12:50PM  ETFs with exposure to Editas Medicine, Inc. : December 19, 2017 Capital Cube
Dec-12-17 08:07AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : December 12, 2017 Capital Cube
Dec-11-17 06:00PM  Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia GlobeNewswire -5.45%
Dec-06-17 11:44AM  Here's Why Editas Medicine Inc. Stock Is Slipping Today Motley Fool -7.75%
07:00AM  Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock GlobeNewswire
Dec-05-17 04:17PM  Editas Medicine, Inc., Announces Offering of Common Stock GlobeNewswire
Nov-30-17 03:58PM  Here's Why Sangamo Therapeutics Rose as Much as 14.9% Thursday Motley Fool
Nov-22-17 01:15PM  FDA warns against do it yourself gene therapy kits American City Business Journals +8.86%
Nov-14-17 07:34AM  Disruptor Alert: These 5 Companies Are Changing Healthcare Motley Fool
07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 05:26PM  Edited Transcript of EDIT earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-09-17 09:00AM  Editas Medicine Keeps Moving Forward Motley Fool
07:53AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : November 9, 2017 Capital Cube
Nov-08-17 04:24PM  Barclays: Editas Medicine On Track To File New Drug App Next Year Benzinga
12:25PM  Here's Why Editas Medicine Collapsed at Market Open Today Motley Fool
Nov-07-17 04:13PM  Editas reports 3Q loss Associated Press
04:03PM  Editas Medicine Announces Third Quarter 2017 Results and Update GlobeNewswire
03:48PM  Editas CEO to testify at U.S. Senate hearing on gene editing potential, ethics American City Business Journals
07:03AM  What Investors Should Know About Editas Medicine Incs (EDIT) Financial Strength Simply Wall St.
Nov-03-17 08:00AM  Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results GlobeNewswire
Oct-31-17 12:09PM  Editas Medicine, Inc. Value Analysis (NASDAQ:EDIT) : October 31, 2017 Capital Cube
11:37AM  ETFs with exposure to Editas Medicine, Inc. : October 31, 2017 Capital Cube
Oct-30-17 08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : October 30, 2017 Capital Cube +7.27%
Oct-19-17 12:45PM  Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice GlobeNewswire
Oct-03-17 08:00AM  Editas Medicine to Participate in Investor Conferences in October GlobeNewswire
Oct-02-17 04:10PM  Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing Investor's Business Daily
Sep-27-17 09:46AM  Axovant Rises After Tuesday's Plunge - Biotech Movers TheStreet.com
Sep-26-17 04:01PM  Editas Medicine Receives EMAs Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10 GlobeNewswire
Sep-12-17 08:00AM  Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10) GlobeNewswire
Sep-07-17 09:30PM  Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August Motley Fool
Sep-05-17 08:00AM  Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference GlobeNewswire
Aug-31-17 11:29AM  How a CRISPR, gene-editing technology, patent ruling could move stocks Harvest Exchange
Aug-20-17 02:02PM  This Stock Could Be the Tesla of Healthcare Motley Fool
Aug-14-17 08:16PM  Edited Transcript of EDIT earnings conference call or presentation 9-Aug-17 9:00pm GMT Thomson Reuters StreetEvents +5.51%
08:15AM  Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3% Zacks
07:30AM  [$$] Gormley's Take: Biotech Companies Are Steering Clear of Gene Editing's Ethical Concerns The Wall Street Journal
Aug-13-17 07:06AM  Edited Transcript of EDIT earnings conference call or presentation 15-May-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:02PM  Editas reports 2Q loss Associated Press
04:03PM  Editas Medicine Announces Second Quarter 2017 Results and Update GlobeNewswire
04:01PM  Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment GlobeNewswire
Aug-08-17 09:56AM  Here's Why Editas Medicine Rose as Much as 15.9% Monday Motley Fool
Aug-07-17 08:00AM  Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results GlobeNewswire +9.09%
Jul-31-17 08:36AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : July 31, 2017 Capital Cube
Jul-24-17 03:34PM  ETFs with exposure to Editas Medicine, Inc. : July 24, 2017 Capital Cube
Jul-18-17 09:31AM  Should You Buy Into the Hype Surrounding These Stocks? Motley Fool -5.10%
08:10AM  Today's Research Reports on Stocks to Watch: Editas Medicine and Cymabay Therapeutics Accesswire
Jul-15-17 03:40PM  Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Motley Fool
Jul-14-17 02:06PM  ETFs with exposure to Editas Medicine, Inc. : July 14, 2017 Capital Cube
Jul-11-17 05:08PM  Here's Why Editas Medicine Inc. Bounced Up 20% in June Motley Fool
09:16AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : July 11, 2017 Capital Cube
Jul-03-17 04:23PM  Editas Medicine, Inc. Value Analysis (NASDAQ:EDIT) : July 3, 2017 Capital Cube
Jun-30-17 09:27AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : June 30, 2017 Capital Cube
Jun-13-17 08:00AM  Editas Medicine to Participate in Investor Conferences in June GlobeNewswire
May-31-17 04:01PM  Editas Medicine Names Andrew Hirsch to Board of Directors GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Editas Medicine Accesswire
May-30-17 04:50PM  Study raises concerns over gene-editing, hitting Cambridge biotechs hard American City Business Journals -11.97%
04:17PM  Here's Why Editas Medicine Fell as Much as 15.7% Today Motley Fool
May-16-17 01:40PM  Is Editas Facing a New Reality in CRISPR Land? 24/7 Wall St. -8.55%
09:34AM  Biotech Movers: Akebia, Editas, Novavax TheStreet.com
May-15-17 06:32PM  Editas reports 1Q loss Associated Press
04:01PM  Editas Medicine Announces First Quarter 2017 Results and Update GlobeNewswire
03:30PM  Investor Network: Editas Medicine, Inc. to Host Earnings Call Accesswire
May-13-17 11:05AM  Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas GlobeNewswire
May-12-17 08:45AM  Why Editas Medicine (EDIT) Might Surprise This Earnings Season Zacks
May-11-17 09:15AM  Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
May-09-17 05:42PM  Allergan Says It Continues to Look at Stepping-Stone Deals TheStreet.com
09:48AM  Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store? Zacks
May-08-17 04:01PM  Editas Medicine to Present at Investor Conferences in May GlobeNewswire
04:01PM  Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results GlobeNewswire
02:45PM  Cambridge gene editing firm CRISPR to use delivery tech honed at MIT American City Business Journals
Apr-27-17 11:35AM  CEOs of top gene-editing firms got huge compensation hikes last year American City Business Journals
Apr-25-17 09:29AM  Opening Bell, April 25, 2017 CNBC Videos
09:15AM  Today's Bell Ringer, April 25, 2017 CNBC Videos
Apr-24-17 02:18PM  Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire
10:00AM  Editas Medicine, Inc. (Nasdaq: EDIT) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Apr-13-17 02:05PM  Editas foes add legal firepower as gene-editing case goes to appeal American City Business Journals
Mar-31-17 04:09PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal
Mar-30-17 07:20AM  New Cambridge biotech Tango aims to make cancer its own worst enemy at bizjournals.com
07:20AM  New Cambridge biotech Tango aims to make cancer its own worst enemy American City Business Journals
Mar-29-17 08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017 Capital Cube
08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017
Mar-28-17 06:04AM  Coverage initiated on Editas Medicine by Chardan Capital Markets +5.75%
Mar-22-17 10:30AM  Latest Editas research pact could be worth up to $1 billion at bizjournals.com
Developing gene editing therapies based on CRISPR/Cas9 technology.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bosley KatrinePresident and CEOJan 03Sale35.046,662233,4161,367,769Jan 04 04:09 PM
Bosley KatrinePresident and CEOJan 02Sale33.448,333278,6371,374,431Jan 04 04:09 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Option Exercise3.234,64915,0164,649Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Sale25.064,649116,5100Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Sale24.685,000123,4090Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Sale24.315,000121,5460Dec 19 04:38 PM
Bosley KatrinePresident and CEODec 01Sale29.588,333246,5221,382,764Dec 05 06:08 AM
Hack Andrew A. F.Chief Financial OfficerNov 20Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 20Sale25.355,000126,7320Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Sale24.815,000124,0730Nov 21 04:04 PM
Bosley KatrinePresident and CEONov 01Sale23.648,333196,9661,391,097Nov 03 04:48 PM
Bosley KatrinePresident and CEOOct 02Sale24.788,333206,5251,399,430Oct 04 04:30 PM
Bosley KatrinePresident and CEOSep 05Sale20.206,666134,6811,407,763Sep 06 05:05 PM
Bosley KatrinePresident and CEOSep 01Sale20.4210,000204,1501,414,429Sep 06 05:05 PM
Bosley KatrinePresident and CEOAug 11Sale20.026,666133,4501,424,429Aug 14 04:35 PM
Bosley KatrinePresident and CEOAug 10Sale20.0210,000200,1601,431,095Aug 14 04:35 PM
Cox Gerald FrankChief Medical OfficerJun 02Buy14.154,00056,6004,000Jun 06 04:12 PM
Nikolic BorisDirectorJun 02Buy14.0735,000492,52735,000Jun 06 04:09 PM
Bitterman KevinDirectorMay 22Sale17.001,000,00017,000,0002,797,144May 24 04:38 PM
Glucksmann AlexandraChief Operating OfficerMar 15Option Exercise0.651,000650118,788Mar 17 11:53 AM
Glucksmann AlexandraChief Operating OfficerMar 15Sale26.411,00026,410117,788Mar 17 11:53 AM
Hack Andrew A. F.Chief Financial OfficerFeb 15Option Exercise3.233,0009,6903,000Feb 16 06:41 PM
Glucksmann AlexandraChief Operating OfficerFeb 15Option Exercise0.656,0003,900123,788Feb 16 06:39 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Sale19.203,00057,6000Feb 16 06:41 PM
Glucksmann AlexandraChief Operating OfficerFeb 15Sale20.586,000123,484117,788Feb 16 06:39 PM